(Date:8/29/2008)...esults of a 10-year study published in the August ...found that magnesium sulfate administered to women...he risk of cerebral palsy by 50 percent. The Benef...) trial was conducted in 18 centers in the U.S., i...renatal intervention ever found to reduce the inst...
(Date:8/29/2008)... http://www.aronowitzmd.com [Los An...espected experience in plastic surgery procedures ...consideration may be necessary for these patients,...e an established specialty of procedures for after...es, CA (PRWEB) August 29, 2008 -- Bariatric surger...
(Date:8/28/2008)...ues increase 138% versus Q2 2007 - Nine new Cen...RNewswire-FirstCall/ - CRH Medical Corporation,(CR... three and six months,ended June 30, 2008 (all fig...ths ended June 30, 2008 increased 138% to $1,653,8...7. Revenue for the six months ended June,30, 2008 ...
(Date:8/28/2008)...ion will be based in the Northeast region with mor...xt year, HARRISBURG, Pa., Aug. 28 /PRNewswire-USN...ity has hired a Patient Safety Liaison for the,Nor...eport to the,Pennsylvania Patient Safety Reporting...ylvania citizens., "Last year in focus groups wit...
Breaking Medicine News(10 mins):Health News:National study shows magensium sulfate reduces risk of cerebral palsy in premature births 2Health News:Dr. Joel Aronowitz, Specialist in Los Angeles Body Lift, Announces Plastic Surgery Options After Bariatric Surgery Weight Loss 2Health News:Dr. Joel Aronowitz, Specialist in Los Angeles Body Lift, Announces Plastic Surgery Options After Bariatric Surgery Weight Loss 3Health News:Dr. Joel Aronowitz, Specialist in Los Angeles Body Lift, Announces Plastic Surgery Options After Bariatric Surgery Weight Loss 4Health News:CRH Medical reports Q2 2008 results 2Health News:CRH Medical reports Q2 2008 results 3Health News:CRH Medical reports Q2 2008 results 4Health News:CRH Medical reports Q2 2008 results 5Health News:Pennsylvania Patient Safety Authority Hires Patient Safety Liaison to Help Healthcare Facilities Implement Guidance 2Health News:Pennsylvania Patient Safety Authority Hires Patient Safety Liaison to Help Healthcare Facilities Implement Guidance 3(Date:8/25/2008)...lls Found in Menstrual Blood May Offer Long-Lastin...ed Women, OLDSMAR, Fla., Aug. 25 /- ...ould agree that there never seems to be enough,of ... doing something just,for herself usually pales in...s reality has led many women in need of quality ti...
(Date:8/25/2008)...s., Aug. 25 /- Joseph F. Finn, Jr.,C..., Inc. ("Spherics") for,the benefit of creditors, ...al property will be sold at a sealed bid auction o...se formulation of Levodopa-Carbidopa that,is the c...ease, with global,sales estimated at approximately...
(Date:8/25/2008)...ug. 25 /- Anthera Pharmaceuticals,Inc...loping,anti-inflammatory drugs, today announced th... coronary events with Near-term Cardiovascular,Inf...examine the impact of,varespladib when administere... Syndrome (ACS) event., The FRANCIS trial is desi...
(Date:8/22/2008)... in Trial Sponsored by Medical Research Council, ...- Indevus,Pharmaceuticals, Inc. (Nasdaq: IDEV ) a...tocol MDP 301, a Phase III clinical trial of PRO 2...or the prevention of HIV and other,sexually transm...ited,Kingdom,s Medical Research Council (MRC) and ...
Breaking Medicine Technology:Going Beyond 'Spa Day': Giving Women the Opportunity to Do Something Proactive Which May Lead to Long Term Health Benefits 2Spherics, Inc. Offers Extended Release Formulation for Sustained and Stable Levodopa Levels 2Anthera Pharmaceuticals Advances Global Development Strategy for Varespladib in Patients With Acute Coronary Syndrome With the Initiation of FRANCIS Trial 2Anthera Pharmaceuticals Advances Global Development Strategy for Varespladib in Patients With Acute Coronary Syndrome With the Initiation of FRANCIS Trial 3Indevus Pharmaceuticals Announces Completion of Enrollment in Phase III Trial of PRO 2000 2Indevus Pharmaceuticals Announces Completion of Enrollment in Phase III Trial of PRO 2000 3Indevus Pharmaceuticals Announces Completion of Enrollment in Phase III Trial of PRO 2000 4Indevus Pharmaceuticals Announces Completion of Enrollment in Phase III Trial of PRO 2000 5Arena Pharmaceuticals Selected to Join New NASDAQ NeuroInsights Neurotech Index 842 1Arena Pharmaceuticals Selected to Join New NASDAQ NeuroInsights Neurotech Index 842 2Arena Pharmaceuticals Selected to Join New NASDAQ NeuroInsights Neurotech Index 842 3Positive Glufosfamide Results From a Phase 2 Clinical Trial Presented at European Cancer Conference 28ECCO 29 395 1Positive Glufosfamide Results From a Phase 2 Clinical Trial Presented at European Cancer Conference 28ECCO 29 395 2Positive Glufosfamide Results From a Phase 2 Clinical Trial Presented at European Cancer Conference 28ECCO 29 395 3Positive Glufosfamide Results From a Phase 2 Clinical Trial Presented at European Cancer Conference 28ECCO 29 395 4Heart Attack Survivors Benefit From Rehab 2063 1Heart Attack Survivors Benefit From Rehab 2063 2Mixing large doses of both acetaminophen painkiller and caffeine may increase risk of liver damage 568 1Mixing large doses of both acetaminophen painkiller and caffeine may increase risk of liver damage 568 2... Researchers at,Molecular Insight Pharmaceuticals ...ta on MIP-1072, a radiolabeled, small molecule,mol...iagnosis and,staging of prostate cancer at the 54t...e (SNM) in Washington, D.C. MIP-1072 is,one of two...sis,that Molecular Insight plans to advance into e...
...Corporation,(NASDAQ: CYTO) today reported results ...(samarium Sm-153 lexidronam injection),can be safe...e also,receiving the chemotherapy docetaxel (Taxot...t further evaluation of the combination,regimen fo...ogram.,The results were presented and/or published...
Other Medicine Technology:Molecular Insight Pharmaceuticals, Inc. Presents Preclinical Data,on Molecular Imaging Pharmaceutical for Prostate Cancer 2Molecular Insight Pharmaceuticals, Inc. Presents Preclinical Data,on Molecular Imaging Pharmaceutical for Prostate Cancer 3Molecular Insight Pharmaceuticals, Inc. Presents Preclinical Data,on Molecular Imaging Pharmaceutical for Prostate Cancer 4New Data for Cytogen's QUADRAMET Reported at Annual ASCO Meeting 2New Data for Cytogen's QUADRAMET Reported at Annual ASCO Meeting 3New Data for Cytogen's QUADRAMET Reported at Annual ASCO Meeting 4New Data for Cytogen's QUADRAMET Reported at Annual ASCO Meeting 5New Data for Cytogen's QUADRAMET Reported at Annual ASCO Meeting 6New Data for Cytogen's QUADRAMET Reported at Annual ASCO Meeting 7This fume hood features a one-piece shell molded of polyethylene with a clear acrylic panel that slides on inside tracks. It can be set in an open, closed or intermediate position.
These handy dispensers save space and organize gloves in labs and next to hand washers. Clear acrylic. Many other sizes and custom configurations available.
...e offers the ultimate in versatility combined with...afety. ,Designed to meet the needs of the routin...e more demanding requirements of the specialised u...ories will guarantee that it becomes the first cho...
The Starter Package is a solid solution for setting up your laboratory. The package includes the Vibratome Plus, standard accessory kit, additional mounting blocks, v-block adapter, specimen mounts w
Medicine Products: